Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB

Key Points

• Tudor Investment Corp initiated a new stake in Cytek Biosciences, buying 249,812 shares worth about $867,000 and owning roughly 0.20% of the company at the end of the reporting period; institutional investors now hold about 69.46% of the stock.
• Analyst sentiment is mixed — two Buy, two Hold and two Sell ratings — giving an average rating of Hold and an average price target of $5.38, with recent coverage including Morgan Stanley (equal weight) and TD Cowen (buy).
• Shares opened at $4.30 (12‑month range $2.37–$6.18) with a market cap near $550 million; Cytek reported Q results showing a revenue beat ($62.14M vs. $58.8M) but an EPS miss (‑$0.34) and negative margins/ROE.

Tudor Investment Corp ET AL purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 249,812 shares of the company's stock, valued at approximately $867,000. Tudor Investment Corp ET AL owned 0.20% of Cytek Biosciences at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Federated Hermes Inc. grew its position in Cytek Biosciences by 150.9% during the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after purchasing an additional 4,343 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Cytek Biosciences during the 3rd quarter valued at $43,000. Captrust Financial Advisors purchased a new stake in shares of Cytek Biosciences in the second quarter valued at $43,000. PNC Financial Services Group Inc. lifted its holdings in shares of Cytek Biosciences by 331.8% in the second quarter. PNC Financial Services Group Inc. now owns 16,478 shares of the company's stock valued at $56,000 after purchasing an additional 12,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Cytek Biosciences by 338.1% in the second quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company's stock worth $67,000 after buying an additional 15,250 shares during the period. Hedge funds and other institutional investors own 69.46% of the company's stock.

Wall Street Analysts Forecast Growth

CTKB has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on Cytek Biosciences in a research report on Monday, December 1st. They set an "equal weight" rating and a $6.00 price target on the stock. TD Cowen restated a "buy" rating on shares of Cytek Biosciences in a research report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cytek Biosciences in a research note on Friday. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $5.38.

Cytek Biosciences Stock Down 0.5%

Cytek Biosciences stock opened at $4.30 on Tuesday. Cytek Biosciences, Inc. has a 12 month low of $2.37 and a 12 month high of $6.18. The stock has a market cap of $549.82 million, a P/E ratio of -8.43 and a beta of 1.31. The company's fifty day simple moving average is $4.55 and its 200-day simple moving average is $4.61.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.36). Cytek Biosciences had a negative return on equity of 7.70% and a negative net margin of 33.02%.The firm had revenue of $62.14 million for the quarter, compared to analysts' expectations of $58.80 million. On average, equities research analysts expect that Cytek Biosciences, Inc. will post -0.06 earnings per share for the current fiscal year.

Cytek Biosciences Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.

Want to see what other hedge funds are holding CTKB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.